Pure Medical offers new and specialized medical device technology manufacturers from USA and EU access to a network of distribution partners in the Asia Pacific (with an emphasis on China), Latin America and the Middle East. Our consultancy and expertise ensures Medical/Pharma/Health start-up ventures who seek guidance in the Asia-Pacific, LATAM and ME markets receive critical information. My 20 years of experience in these markets and robust relationships within these territories has been employed with a wide range of technologies as indicated from my prior experience,Pure Medical is also engaged with local NZ academics, Governmental and clinicians assistance in NPD with whom we achieve cutting edge in vivo and in vitro opportunities that do not exist in other markets. The strong healthcare ethic's,, integrity. standards of care and reputation of NZ trials enables expeditious and value based EU and US approval opportunities,

Operating with independence and autonomy from Auckland, NZ under my consultancy and registered NZ company Pure Medical Ltd - International launch of Health and Nutrition products into China for well established Austrian manufacturer who challenges the current market with their pure products. Utilizing my strong local experience in China with Academic, Commercial and Governmental Institutions, I have direct responsibility for driving CBEC and traditional sales and marketing strategies reporting directly to International and CEO internally with Biogena. Complete responsibilities from a ground zero launch position and utilizing strategic market analysis and marketing skills I identified International partners and negotiated contracts. Providing strategic insight and competitive analysis to generate rapid growth from initial product launch through marketing strategies to partner engagement, regulatory approval, sales force training, I orchestrate, present and coordinate promotional visits and public speaking events with leading experts, tradeshow and scientific meeting attendance. I oversee regulatory and best industry practices comply with Chinese regulations and work with Pure Medical's own employees in China and identify best partners.

International Product Launch/Sales Class III Medical Devices – Operating with independence and autonomy from Auckland, NZ under my consultancy and registered NZ company Pure Medical Ltd. I report directly to the Managing Director in Germany. Culturally aware and highly experienced in the ASEAN markets, I leveraged my 15 years’ experience in the medical arena internationally, while my 5 years’ of experience living/working in China was instrumental in propelling this market into the lead sales and profit account internationally for the company.My mandate and achievement was to successfully introduce German (haemostasis and coated technologies) Class III Medical devices into Canada, Asia-Pacific, LATAM and the ME through a network of independent distributors. Complete responsibilities from a ground zero launch position and utilising strategic market analysis and marketing skills I identified International partners and negotiated contracts. Providing strategic insight and competitive analysis to generate rapid growth from initial product launch through marketing strategies to partner engagement, regulatory approval, sales force training, I orchestrated, presented and coordinated promotional visits and public speaking events with leading surgeons, tradeshow and scientific meeting attendance. Enhanced strong network communication partner support using multiple social and online media support combined with frequent travel.Ensured speed to market practises were followed through thorough knowledge of the regulatory landscapes of CE (EU), CFDA (China), TGA (Aust.), KFDA (Korea), SFDA (Saudi Arabia) Health Canada and many others. Drove further acceptance and spearheaded new regulatory traction through establishment of clinical studies in Austria, NZ/Australia, Singapore and Argentina.Developed network and controlled financial results utilising robust strategies to ensure targets were meet and exceeded.

International Launch/Sales Class III Medical Devices - Commencing a 6-month tenure in Shanghai, China and continuing from my NZ base I developed initial launch for start-up US manufacturer of cutting edge haemostatic Class III medical devices SMI. Direct responsibility for internal team development of international sales and marketing materials. I provided competitive market analysis and distributor presentation and public speaking engagement roles. I conducted portfolio presentations at various global locations directly to key distributors/stakeholders and surgeons in EU, Asia-Pac. and the Middle East assisted contract negotiation, providing ongoing relationship management and market research functions. Directly reporting to SMI President and the VP International sales. The success of the launch saw the product licensed to a large US based Cardio-vascular multinational.

Change Management and Sales - Victech Scientific (Shanghai) Co. Ltd was established in 1994 by its parent company Schmidt Scientific (Taiwan) Ltd as a WOFE (wholly owned foreign Enterprise) to distribute medical devices in the PRC. The role assigned was to transition and change the company’s limited Taiwanese portfolio and introduction and contract of innovative US and EU manufacturers technologies.Defined stakeholders’ goals and communicated internally benefits and requirements for newly implemented goals.Overseeing the marketing team, I developed complete company rebranding processes and engaged European and US companies seeking distribution in China. I successfully introduced negotiated and contracted US Haemostatic device (Arista, Medafor Inc, USA), European Othobiological, Demineralised Bone Matrix devices (Isotis, Switzerland), Spinal Orthopaedic Devices (France), Stent technologies (Translumina, Germany). Drove company product regulatory approval presenting and supporting principals CFDA applications in China engaging in direct technical presentations to reviewers. Experience with trauma and spinal orthopaedic, cardiovascular and haemostatic products. Directly reporting to CEO.